SRSF2 mutations drive oncogenesis by activating a global program of aberrant alternative splicing in hematopoietic cells

Recurrent mutations in the splicing factor SRSF2 are associated with poor clinical outcomes in myelodysplastic syndromes (MDS). Their high frequency suggests these mutations drive oncogenesis, yet the molecular explanation for this process is unclear. SRSF2 mutations could directly affect pre-mRNA s...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Leukemia
Main Authors: Liang, Yang, Tebaldi, Toma, Rejeski, Kai, Joshi, Poorval, Stefani, Giovanni, Taylor, Ashley, Song, Yuanbin, Vasic, Radovan, Maziarz, Jamie, Balasubramanian, Kunthavai, Ardasheva, Anastasia, Ding, Alicia, Quattrone, Alessandro, Halene, Stephanie
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6274620/
https://ncbi.nlm.nih.gov/pubmed/29858584
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41375-018-0152-7
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados